XML 40 R44.htm IDEA: XBRL DOCUMENT
v2.4.0.6

Significant Contracts (Details) (USD $) In Millions, unless otherwise specified | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | ---
Apr. 30, 2011 Daiichi Sankyo | Dec. 31, 2012 Daiichi Sankyo | Jul. 31, 2011 Daiichi Sankyo Minimum country | Dec. 31, 2012 Daiichi Sankyo Minimum | Dec. 31, 2012 Daiichi Sankyo Maximum | Oct. 31, 2007 ALIGN item | Dec. 31, 2010 ALIGN | Dec. 31, 2009 ALIGN | Dec. 31, 2011 ALIGN
Licensing Agreements |  |  |  |  |  |  |  |  |
Up-front fee and certain past reimbursements | $ 1.6 |  |  |  |  |  |  |  |
Future milestone payments payable |  | 10.0 |  |  |  |  |  |  |
Period for which royalties will be paid following the first commercial sale of licensed products in the country |  | 10 years |  |  |  |  |  |  |
Notice period for termination of license by the entity for technical, scientific, efficacy, safety, or commercial reasons |  | 6 months |  |  |  |  |  |  |
Notice period for termination of license after launch of a sapacitabine-based product by the entity, or by either party for material default |  | 12 months |  |  |  |  |  |  |
Number of countries for which regulatory approval is required by September 2011 to sell sapacitabine as per termination right waived after amendment to the agreement |  |  | 1 |  |  |  |  |  |
Percentage of increase in royalty due on future net sales of sapacitabine after amendment |  |  |  | 1.25% | 1.50% |  |  |  |
Number of products for which exclusive rights acquired to sell and distribute products |  |  |  |  |  | 3 |  |  |
Commitment payments |  |  |  |  |  |  |  | 1.3 |
Commitment paid |  |  |  |  |  |  | 0.7 | 0.6 |
Minimum purchase obligation |  |  |  |  |  |  |  |  | $ 0.2

X
- Definition The floor amount as of the balance sheet date that the entity must expend to satisfy the terms of assets purchase agreement. + References No definition available. + Details
Name: | cycc_LicenseAgreementDistributionRightsPurchaseCommitmentRemainingMinimumAmountCommitted
Namespace Prefix: | cycc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the milestone payments paid by the entity under certain contractual agreements. + References No definition available. + Details
Name: | cycc_LicenseAgreementMilestonePaymentsPaid
Namespace Prefix: | cycc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the notice period for the termination of license after a launch of a sapacitabine-based product, or by either party for material default. + References No definition available. + Details
Name: | cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault
Namespace Prefix: | cycc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of countries for which regulatory approval is required by September 2011 to sell sapacitabine as per termination right that counter party possessed under the provision of agreement which is waived after amendment to the agreement. + References No definition available. + Details
Name: | cycc_LicenseAgreementNumberOfCountriesForWhichRegulatoryApprovalRequiredBySeptember2011ToSellSapacitabineUnderTerminationRightWaivedAfterAmendment
Namespace Prefix: | cycc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period for which royalties will be paid following the first commercial sale of licensed products in the country. + References No definition available. + Details
Name: | cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry
Namespace Prefix: | cycc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The potential future milestone payments required to be made under certain contractual agreements. + References No definition available. + Details
Name: | cycc_LicenseAgreementPotentialFutureMilestonePayments
Namespace Prefix: | cycc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the notice period for the termination of license by the reporting entity for technical, scientific, efficacy, safety, or commercial reasons. + References No definition available. + Details
Name: | cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason
Namespace Prefix: | cycc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the increase in royalty due from the entity to the counter party on future net sales depending on the level of net sales realized. + References No definition available. + Details
Name: | cycc_LossContingenciesContingentIncreaseInRoyaltyDueOnFutureNetSales
Namespace Prefix: | cycc_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of payments made under the long term purchase commitments. + References No definition available. + Details
Name: | cycc_PaymentsMadeUnderLongTermSupplyCommitment
Namespace Prefix: | cycc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the number of products for which distribution rights, for the exclusive rights to sell and distribute products, acquired by the entity under assets purchase agreement. + References No definition available. + Details
Name: | cycc_PurchaseCommitmentNumberOfProducts
Namespace Prefix: | cycc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The minimum amount the entity agreed to spend under the long-term purchase commitment. + References No definition available. + Details
Name: | us-gaap_LongTermPurchaseCommitmentAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration